XUE [Xueda Education] SC 13D/A: (Original Filing)
[]
EFUT [eFuture] 6-K: eFuture Announces Receipt of Preliminary Non-Binding Proposal From
[eFuture Announces Receipt of Preliminary Non-Binding Proposal From Shiji, Its Controlling Shareholder BEIJING, June 06, 2016 (GLOBE NEWSWIRE) -- eFuture Holding Inc. (Nasdaq:EFUT) (the “Company” or “eFuture”), a leading software and solution provider and a mobile business enabler to China's retail and consumer goods industries, today announced receipt of an unsolicited preliminary non-binding proposal to acquire all the remaining outstanding] [Form 6-K 001-33113 eFuture Holding Inc. Room A1103, A1105, A1106-07, Building A, Note: Note: eFuture Holding Inc. Kevin King Chairman 6-K 1 f6k_060616.htm FORM 6-K]
IDI [IDI] 8-K: (Original Filing)
[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest Event Reported): June 1, 2016 IDI, Inc. Delaware 333-158336 77-0688094 _____________________ _____________ ______________ of incorporation) Identification No.) 2650 North Military Trail, Suite 300, Boca Raton, Florida 33431 _________________________________ ___________ 561-757-4000 Not Applicable Top of the Form Item 5.07. Submission of Matters to a Vote of Security Holders. On June 1,]
CBPO [China Biologic Products] 424B7: (Original Filing)
[7) Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued June 2, 2016 (To Prospectus dated June 5, 2015) 2,775,000 Shares China Biologic Products, Inc. Common Stock The selling stockholders identified in this prospectus supplement are offering 2,775,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common stock is listed on]
IDI [IDI] 8-K: FORM 8-K CURRENT REPORT Date of Report (Date
[FORM 8-K CURRENT REPORT Date of Report (Date of Earliest Event Reported): June 1, 2016 IDI, Inc. Delaware 333-158336 77-0688094 _____________________ _____________ ______________ of incorporation) Identification No.) 2650 North Military Trail, Suite 300, Boca Raton, Florida 33431 _________________________________ ___________ 561-757-4000 Not Applicable Top of the Form Item 5.07. Submission of Matters to a Vote of Security Holders. On June 1,]
CBPO [China Biologic Products] 424B7: 7) Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued June
[7) Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued June 2, 2016 (To Prospectus dated June 5, 2015) 2,775,000 Shares China Biologic Products, Inc. Common Stock The selling stockholders identified in this prospectus supplement are offering 2,775,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common stock is listed on]
YZC [YANZHOU COAL MINING CO] 6-K: (Original Filing)
[Yanzhou Coal Mining Company Limited Date By Zhang Baocai Director YANZHOU COAL MINING COMPANY LIMITED (A joint stock limited company incorporated in the Peoples Republic of China with limited liability) (Stock Code: 1171) SECOND ANNOUNCEMENT TO CREDITORS OF THE COMPANY IN RELATION TO GENERAL MANDATE]
CBPO [China Biologic Products] 8-K: (Original Filing)
[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 2,775,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT June 2, 2016 June 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares] [June 6, 2016 China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Shares Selling Stockholders Underwriting Agreement We understand that 2,775,000 shares of Common Stock (the “ As legal counsel to] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – June 2, 2016 The shares to be sold in this offering represent approximately 10.4 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] []
